Evidence Hub

Relations Between Performance Enhancement Drugs and Health-defining Parameters During the Competition Preparation Period of World-class Bodybuilders

Magdalena Wiącek, Bartosz Trąbka, Leszek Markuszewski, Ryszard Tomasiuk, Igor Z. Zubrzycki

Research Square, 2021

2 citations

Abstract

Abstract Fluctuations in biochemical parameters defining cardiovascular, liver and muscoskeletal health were analyzed to evaluate the health status of world class bodybuilders using performance enhancement drugs such as anabolic-androgenic steroids (AAS) [testosterone propionate, drostanolone propionate (Masteron), trenbolone acetate (Finajet), oxandrolone (Anavar), stanozolol (Winstrol) and boldenone undecylenate], human growth hormone (HGH) and “fat-burning drugs” [triiodothyronine (t3), clenbuterol, mesterolone (Proviron), tamoxifen citrate (Nolvadex) and 2,4-Dinitrophenol (2,4-DNP)], and a 6-month preparation period. Changes in serum levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), aspartate aminotransferase (AST), alanine transaminase (ALT), and bilirubin, as well as body mass (BM) and total body fat percentage (BF%), were measured as a function of the competition preparation period. The study shows a continuous increase in BM, accompanied by a decrease in BF% to the physiologically optimal level. TC levels varied significantly within the desired concentration range (TC 0.58 mkat / L and > 0.91 mkat / L. Bilirubin concentration fluctuated within the desirable limits (3.42 mmol / L ≤ Bilirubin < 2.53 mmol / L), and urea concentration were between desirable (3.2 mmol / L ≤ Urea < 7.9 mmol / L) and high values (Urea ≥ 7.9 mmol / L). Although most of the changes are within physiologically acceptable…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free